%First Table: Part 1
\begin{landscape}
\begin{table}[p]
\scriptsize
\centering
\caption[Autophagy modulation as a therapy in \textit{in vitro} models of neurodegenerative diseases]{Autophagy modulation as a therapy in \textit{in vitro} models of neurodegenerative diseases}
\label{tab:table1}
\begin{tabular}{lcccccc}	
\toprule
& Autophagy modulators & FDA-approved & Disease model & Mutant protein & Brain region (cell type) & \textbf{cont.}\\
\midrule
\multirow{3}{*}{mTOR dependent} & \multirow{3}{*}{Rapamycin} & \multirow{3}{*}{Yes} & \multirow{3}{*}{AD} & Tau\textsubscript{P301L} & COS-7 & \multirow{2}{*}{\textbf{1}}\\
& & & & APP751/7PA22 & \makecell{Chinese hamster \\ ovary cells (7PA2 cells)} & \\\cmidrule[0.5pt]{2-7}
& Temsirolimus (CCI-779) & Yes & AD & APP\textsubscript{695} & HEK 293 cells & \textbf{2} \\
\midrule
\multirow{13}{*}{mToR independent}& \multirow{4}{*}{Cilostazol} & \multirow{4}{*}{Yes} & \multirow{4}{*}{AD} & APP\textsubscript{695} & \multirow{4}{*}{N2a cells} & \multirow{4}{*}{\textbf{3}} \\
& & & & A$\beta$\textsubscript{1- 42} & & \\
& & & & Retinoic acid & \\
& & & & APP\textsubscript{695} & \\\cmidrule{2-7}
& Resveratrol & Yes & AD & A$\beta$\textsubscript{1- 42} & N2a cells & \textbf{4} \\\cmidrule{2-7}
& \multirow{2}{*}{Trehalose} & \multirow{2}{*}{Yes} & Taupathy & Tau\textsubscript{rd}$\Delta$K280 & N2a cells & \multirow{2}{*}{\textbf{5}} \\
& & & AD & A$\beta$40 \& 42 & SH-SY-5Y & \\\cmidrule{2-7}
& \multirow{4}{*}{Rilmenidine} & \multirow{4}{*}{Yes} & HD & htt & PC12 & \multirow{4}{*}{\textbf{6}} \\
& & & PD & $\alpha$-synuclein & PC12 &\\
& & & HD & htt & SK-N-SH & \\ 
& & & ALS & SOD1A4V & NSC-34 cells &\\\cmidrule{2-7}
& \multirow{4}{*}{SMER28} & \multirow{4}{*}{Yes} & \multirow{4}{*}{AD} & CTF$\beta$ & MEF cells & \multirow{4}{*}{\textbf{7}} \\
& & & & \multirow{3}{*}{APP\textsubscript{695}} & N2a cells & \\
& & & & & MEF cells & \\
& & & & & N2a cells & \\
\bottomrule
\end{tabular}
\end{table}
\end{landscape}

%First Table: Part 2
\begin{landscape}
\begin{table}[p]
\scriptsize
\centering
\caption*{Autophagy modulation as a therapy in \textit{in vitro} models of neurodegenerative diseases \textbf{\textit{(continued)}}}

\begin{tabular}{cccccccc}
\toprule
\textbf{cont.} & Dose & Duration & Basal flux & \makecell{Induced flux \\inhibition} & \makecell{Assessment for \\ aggregation} & \makecell{Assessment for \\ autophagy} & References \\
\midrule
\multirow{2}{*}{\textbf{1}} & 0.2 $\mu$g/ml & 48 h & - & 3MA & WB (Tau) & - & \citet{Berger2006} \\
& 0.5, 5 \& 50 $\mu$g/ml & 24 h & - & - & Elisa (A$\beta$42) & - & \citet{Caccamo2010} \\\cmidrule{1-8}
\textbf{2} & 100 nM & 24 h & - & - & \makecell{WB (APP, C99 \& C88) \\ \& Elisa (A$\beta$40/42)} & WB (LC3II \& p62) & \citet{Jiang2014a} \\\cmidrule{1-8}
\multirow{4}{*}{\textbf{3}} & 10 $\mu$M & - & - & - & \makecell{Elisa (A$\beta$40/42) \& \\ FM (APP-CTF$\beta$)} & FM (LC3 II) & \citet{Park2016} \\\cmidrule{8-8}
& 3, 10 \& 30 $\mu$M & \multirow{4}{*}{3 h} & - & - & - & WB (beclin 1, ATG5) & \multirow{6}{*}{\citet{Lee2015}} \\
& 10 $\mu$M & & - & 3 MA & - & WB (LC3 II) & \\
& 10 $\mu$M \& 30 $\mu$M & & - & - & \makecell{Elisa (A$\beta$1-42) \& \\ WB (APP-CTF$\beta$ \& A$\beta$)} & WB (beclin 1, ATG5) \\\cmidrule{1-7}
\textbf{4} & 20 $\mu$M & 3h & - & - & - & WB (beclin 1, ATG5) \\\cmidrule{1-8}
\multirow{4}{*}{\textbf{5}} & 12.5, 25 \& 50 mM & 24 h & - & - & - & WB (LC3 II) & \multirow{4}{*}{\citet{Kruger2012}} \\
& \multirow{4}{*}{50 mM} & 12, 24, 48 \& 72 h & - & - & - & WB (LC3 II) \\
& & \multirow{2}{*}{24 h} & - & - & FM \& WB (Tau) & FM (LC3) \\
& & & BafA1 & BafA1 & - & WB (LC3 II) \\\cmidrule{8-8}
& 1, 10 \& 50 mM & 12 h & - & - & FM (A$\beta$40 \& 42) & - & \citet{Liu2005} \\\cmidrule{1-8}
\multirow{6}{*}{\textbf{6}} & \multirow{3}{*}{1 $\mu$M} & \multirow{2}{*}{24 h} & \multirow{2}{*}{-} & \multirow{2}{*}{-} & - & WB (LC3 II) & \citet{Rose2010} \\\cmidrule{8-8}
& & & - & - & WB ($\alpha$-synuclein ) & WB (LC3 II) & \multirow{3}{*}{\citet{Williams2008}} \\
& & 48 h & - & - & WB (ï»¿EGFP-HDQ74) & - \\
& 0.3, 1 \& 3 $\mu$M & 24 h & - & - & - & WB (LC3 II) & \\\cmidrule{8-8}
& \multirow{2}{*}{10 $\mu$M} & \multirow{2}{*}{24 h} & BafA1 & BafA1 & - & WB (LC3 II) & \multirow{2}{*}{\citet{Perera2018}} \\
& & & - & - & WB (SOD1) & WB (LC3 II \& p62) \\\cmidrule{1-8}
\multirow{6}{*}{\textbf{7}} & 10 $\mu$M &\multirow{4}{*}{16h} & - & - & WB (CTF$\beta$) & - & \multirow{6}{*}{\citet{Tian2011}}\\
& 3, 10, 30 \& 50 $\mu$M & & - & - & \makecell{WB (APP-CTF \& \\ APP-FL)} & - & \\
& 50 $\mu$M & & - & - & \multirow{2}{*}{\makecell{Elisa (A$\beta$1-42) \& \\ WB (APP-CTF \& APP-FL)}} & WB (LC3 II) & \\
& & & BafA1 & BafA1 & & - \\
& 1, 3, 10, 30 \& 50 $\mu$M & \multirow{2}{*}{6 h}& - & - & WB (APP-CTF) & - \\
& 50 $\mu$ & & - & - & \makecell{WB (APP-CTF) \& \\ FM (APP \& APP-CTF)} & \makecell{WB (LC3 II) \& \\ FM (EGFP-LC3)}\\
\bottomrule
\end{tabular}
\end{table}
\end{landscape}